Orenitram

Indicated For

Pulmonary Arterial Hypertension (PAH), PAH related to interstitial lung disease

About This Medication

# United Therapeutics Cares Patient Assistance Program Patient Guide: How to Get Orenitram (treprostinil) at Low or No Cost Orenitram (treprostinil) is an oral medication used to treat **pulmonary arterial hypertension (PAH)**, including PAH related to interstitial lung disease (PH-ILD), by helping to relax and widen blood vessels in the lungs to improve blood flow and reduce symptoms like shortness of breath and fatigue.[1][3][5] The **United Therapeutics Cares Patient Assistance Program** offers free Orenitram to eligible uninsured or underinsured U.S. residents who meet financial need criteria, providing crucial support for managing this serious condition without high out-of-pocket costs.[5][9] ## Who Qualifies for the Program? This program is designed for **patients who are uninsured or underinsured** and facing financial hardship with Orenitram costs. You must be a **U.S. resident** (including Puerto Rico) prescribed Orenitram for an FDA-approved use, such as PAH.[2][5][9] Key eligibility factors include: - No or limited insurance coverage that doesn't fully cover the medication. - Demonstrated financial need (specific income limits not publicly detailed; case-by-case review applies).[9] - Not enrolled in government programs like Medicare or Medicaid for some assistance types, though patient assistance may have nuances.[2][5] **Important note**: Patients on Medicare, Medicaid, or other federal/state programs may not qualify for co-pay assistance but could be eligible for this patient assistance program if uninsured/underinsured—confirm with the program team.[2][5] ## About Orenitram (treprostinil) Orenitram is a **prostaglandin analog** taken as extended-release tablets, typically multiple times a day with food to improve tolerance. It's part of a treatment plan for **PAH (WHO Group 1)** to delay disease progression, improve exercise capacity, and reduce clinical worsening.[1][3] Common side effects include headache, diarrhea, nausea, and jaw pain; your doctor will titrate the dose slowly to minimize these. Always follow your healthcare provider's instructions, as Orenitram requires monitoring through a specialty pharmacy.[1][7] United Therapeutics Cares also offers a **90-Day Trial Program** for eligible patients to try Orenitram at no cost, helping assess tolerance before long-term commitment.[1] ## Income Eligibility Breakdown Specific income thresholds (e.g., Federal Poverty Level percentages) are **not publicly detailed**; eligibility is determined individually based on financial documentation and household size. Contact the program for a personalized assessment.[9] Here's a general overview: | Household Size | Typical Threshold Example (if FPL-based, for illustration)* | Notes | |---------------|-----------------------------------------------------------|-------| | Individual | Not specified; case-by-case | Proof of income required | | Couple | Not specified; case-by-case | Household income reviewed | | Family of 3 | Not specified; case-by-case | Includes dependents | | Family of 4+ | Not specified; case-by-case | Larger families may have flexibility | *These are illustrative; actual eligibility uses detailed financial review. Program notes: "Eligibility requirements for uninsured or underinsured; specific income thresholds not detailed."[9] ## Insurance Requirements - **Uninsured or underinsured patients** are primary candidates.[5][9] - **Medicare, Medicaid, or federal/state government programs** may disqualify you from co-pay help but not necessarily patient assistance—verify eligibility.[2][5] - Commercial (private) insurance patients may access co-pay programs separately, but this guide focuses on patient assistance for those without adequate coverage.[2] - State restrictions apply; residents of select states may have limited eligibility.[1][2] Your dedicated Patient Navigator will review your coverage and explore all options.[3][6] ## Step-by-Step Application Process 1. **Discuss with your healthcare provider (HCP)**: Share this guide and ask them to enroll you. They handle submission.[5][9] 2. **Gather required documents**: - Valid **prescription** for Orenitram. - **Proof of residency** (e.g., utility bill, driver's license). - **HCP enrollment form** (Request for Support Form, includes patient info, income details, diagnosis).[9] 3. **Call United Therapeutics Cares**: Dial **(844) 864-8437** (Mon-Fri, 8:30 am–7 pm ET) to start. Your HCP faxes the form to 800-380-5294 or emails assist@unither.com.[9] 4. **Work with your Patient Navigator**: They'll guide benefits investigation, confirm eligibility, and coordinate with specialty pharmacies.[3][6] 5. **Approval notification**: If approved, you'll be notified, and medication ships directly.[5] **Application method**: Primarily by phone/HCP submission; no online portal listed.[9] ## Timeline and Delivery - **Processing time**: Typically **2-4 weeks** after complete submission.[9] - **Delivery**: Shipped free to your home via a **specialty pharmacy partner**. They'll handle refills and check-ins.[5][7] - **Reauthorization**: Required periodically; your HCP resubmits to continue supply.[9] Expect ongoing support from day one, including education and prescription monitoring.[4] ## Alternatives if Denied - **Appeal**: Ask your Navigator for appeal guidance; provide additional financial docs.[3] - **90-Day Trial Program**: Free trial for eligible patients via HCP.[1] - **Co-Pay Assistance**: If commercially insured (not government programs).[2] - **Other resources**: PH Association lists additional PAH aids; explore state programs or generic options (none listed as biosimilars).[5] - Contact **PH Association** or call 844-864-8437 for personalized alternatives.[5] ## Disclaimer This guide is for informational purposes based on available program details as of March 2026. Eligibility, terms, and availability can change; state laws may restrict access. Always consult your HCP and the program directly at (844) 864-8437 for the latest info. United Therapeutics reserves rights to modify or end the program. Not a substitute for medical advice.

Program information last verified: March 30, 2026